{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T17:15:41Z","timestamp":1786554941008,"version":"build-2736575974"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Chronic plaque psoriasis is a persistent inflammatory skin condition characterized by erythematous, scaly plaques, significantly impairing the quality of life of affected individuals. Mirikizumab, a humanized monoclonal antibody targeting interleukin-23 (IL-23) p19 subunit, has shown promising efficacy in managing moderate-to-severe cases of this disease. This meta-analysis aims to evaluate the efficacy and safety of mirikizumab in comparison to placebo or other active treatments in this patient population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A systematic review of randomized controlled trials (RCTs) was conducted. Eligible studies were identified through searches of major databases. The primary endpoint was clinical response measured by Psoriasis Area and Severity Index (PASI) improvement. Safety outcomes were evaluated based on the frequency of events. Data were pooled using a random-effects model to calculate relative risk and mean differences across studies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Mirikizumab significantly increased the rates of achieving PASI 100, PASI 90, and PASI 75 compared to placebo. Mirikizumab also demonstrated superior efficacy in various secondary outcomes compared to placebo. Safety analysis indicated no significant differences in overall treatment-emergent adverse events (TEAEs) or serious adverse events (SAEs), although upper respiratory tract infections occurred more frequently in the mirikizumab group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Mirikizumab demonstrated a significant improvement in PASI scores compared to placebo and other treatments for chronic plaque psoriasis. Its IL-23 inhibition mechanism suggests a promising therapeutic option with a favorable safety profile. Further research could solidify its position in long-term psoriasis management.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p><jats:uri>https:\/\/www.crd.york.ac.uk\/PROSPERO\/<\/jats:uri>, identifier [CRD42024594843].<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2025.1591787","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T04:10:43Z","timestamp":1753157443000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of mirikizumab (LY3074828) in chronic plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.3389","volume":"12","author":[{"given":"Taimoor","family":"Ashraf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand Kumar","family":"Malani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dileep","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja Subhash","family":"Sagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahil","family":"Raj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Payal","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aanchal","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simran","family":"Bajaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Abdul","family":"Basit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Murad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikash","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayush","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"471","DOI":"10.4103\/2229-5178.193906","article-title":"Psoriasis: epidemiology, clinical features, co-morbidities, and clinical scoring","volume":"7","author":"Dogra","year":"2016","journal-title":"Indian Dermatol Online J"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2147\/PTT.S64950","article-title":"Current knowledge on psoriasis and autoimmune diseases","volume":"6","author":"McCormick","year":"2016","journal-title":"Psoriasis"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1111\/bjd.18245","article-title":"Management of psoriasis as a systemic disease: what is the evidence?","volume":"182","author":"Korman","year":"2020","journal-title":"Br J Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1097\/MS9.0000000000002797","article-title":"Effect of topical treatment with urea in ichthyosis, atopic dermatitis, psoriasis, and other skin conditions\u2014a systematic review","volume":"87","author":"Jawed","year":"2024","journal-title":"Ann Med Surg"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.2147\/CCID.S420850","article-title":"Cellular mechanisms of psoriasis pathogenesis: a systemic review","volume":"16","author":"Wu","year":"2023","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.4049\/jimmunol.1800013","article-title":"Discovery of the IL-23\/IL-17 signaling pathway and the treatment of psoriasis","volume":"201","author":"Hawkes","year":"2018","journal-title":"J Immunol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1046\/j.1468-3083.2000.00134.x","article-title":"Quality of life of psoriasis patients","volume":"14","author":"Gupta","year":"2000","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref9","first-page":"553","article-title":"Study on the impact of psoriasis on quality of life: psychological, social and financial implications","volume":"32","author":"Bulat","year":"2020","journal-title":"Psychiatr Danub"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1046\/j.1087-0024.2003.09110.x","article-title":"Quality of life in patients with psoriasis: a systematic literature review","volume":"9","author":"De Korte","year":"2004","journal-title":"J Invest Dermatol Symp Proc"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/bjd.16332","article-title":"A multidimensional assessment of the burden of psoriasis: results from a multinational dermatologist and patient survey","volume":"179","author":"Griffiths","year":"2018","journal-title":"Br J Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00403-024-03569-x","article-title":"Comparable efficacy of bimekizumab for hidradenitis suppurativa with two- and four-week dosing intervals: a systematic review and meta-analysis","volume":"317","author":"Raja","year":"2025","journal-title":"Arch Dermatol Res"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/jid.2014.530","article-title":"The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries","volume":"135","author":"Dalgard","year":"2015","journal-title":"J Invest Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1007\/s00403-024-03502-2","article-title":"Clinical benefits of delgocitinib cream for chronic hand eczema: a systematic review and meta-analysis","volume":"316","author":"Raja","year":"2024","journal-title":"Arch Dermatol Res"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/bjd.17628","article-title":"Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase II study","volume":"181","author":"Reich","year":"2019","journal-title":"Br J Dermatol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1124\/jpet.122.001512","article-title":"Generation and characterization of mirikizumab, a humanized monoclonal antibody targeting the p19 subunit of IL-23","volume":"387","author":"Steere","year":"2023","journal-title":"J Pharmacol Exp Ther"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1111\/bjd.21743","article-title":"Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1)","volume":"187","author":"Blauvelt","year":"2022","journal-title":"Br J Dermatol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e542","DOI":"10.1016\/S2665-9913(23)00120-0","article-title":"Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study","volume":"5","author":"Papp","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"j4008","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13643-018-0699-4","article-title":"Registration of systematic reviews in PROSPERO: 30,000 records and counting","volume":"7","author":"Page","year":"2018","journal-title":"Syst Rev"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/BTT.S252578","article-title":"Biologic treatments of psoriasis: an update for the clinician","volume":"15","author":"Brownstone","year":"2021","journal-title":"Biologics"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"13313","DOI":"10.3390\/ijms241713313","article-title":"Challenges and future trends in the treatment of psoriasis","volume":"24","author":"Lee","year":"2023","journal-title":"Int J Mol Sci"},{"key":"ref26","first-page":"S2","article-title":"Pathogenesis and treatment of psoriasis: exploiting pathophysiological pathways for precision medicine","volume":"33","author":"Alwan","year":"2024","journal-title":"Clin Exp Rheumatol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1053\/j.gastro.2019.08.043","article-title":"Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s40257-020-00578-0","article-title":"Use of IL-23 inhibitors for the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review","volume":"22","author":"Yang","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1111\/jdv.14433","article-title":"The role of IL-23 and the IL-23\/TH 17 immune axis in the pathogenesis and treatment of psoriasis","volume":"31","author":"Girolomoni","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"611256","DOI":"10.3389\/fimmu.2021.611256","article-title":"The IL23-IL17 immune Axis in the treatment of ulcerative colitis: successes, defeats, and ongoing challenges","volume":"12","author":"Noviello","year":"2021","journal-title":"Front Immunol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1053\/j.gastro.2021.10.050","article-title":"Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with Crohn\u2019s disease","volume":"162","author":"Sands","year":"2022","journal-title":"Gastroenterology"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","article-title":"Mirikizumab as induction and maintenance therapy for ulcerative colitis","volume":"388","author":"D\u2019Haens","year":"2023","journal-title":"N Engl J Med"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"ii20","DOI":"10.1093\/ecco-jcc\/jjac023","article-title":"What can IBD specialists learn from IL-23 trials in dermatology?","volume":"16","author":"Valenti","year":"2022","journal-title":"J Crohns Colitis"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1591787\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T04:10:44Z","timestamp":1753157444000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1591787\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":33,"alternative-id":["10.3389\/fmed.2025.1591787"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1591787","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,22]]},"article-number":"1591787"}}